Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kwang Hyun | - |
dc.contributor.author | Lee, Hyung Ho | - |
dc.contributor.author | Yoon, Young Eun | - |
dc.contributor.author | Na, Joon Chae | - |
dc.contributor.author | Kim, Sook Young | - |
dc.contributor.author | Cho, Young In | - |
dc.contributor.author | Hong, Sung Joon | - |
dc.contributor.author | Han, Woong Kyu | - |
dc.date.accessioned | 2022-07-12T17:17:32Z | - |
dc.date.available | 2022-07-12T17:17:32Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/150744 | - |
dc.description.abstract | To determine the suitability of serum endocan (ESM-1) levels for diagnosing and monitoring renal cell carcinoma (RCC), we measure serum ESM-1 levels in 56 RCC patients who had undergone radical or partial nephrectomies and 56 age-and sex-matched healthy kidney donors. Measurements were made before and 1 month and 3 months after surgery. The areas under the curve (AUCs) were determined from receiver operating characteristic (ROC) analyses. RCC patients had higher mean serum ESM-1 levels than control subjects (0.59 +/- 0.07 vs. 0.52 +/- 0.08 ng/mL, P < 0.001), with an AUC of 0.721 (95% CI: 0.628-0.817). In patients with tumors larger than 2 cm (n = 40) and those with clear-cell histology (n = 44), the AUCs for ESM-1 were 0.771 and 0.721, respectively. In control subjects, serum ESM-1 levels were higher in older (>50 years) individuals (P < 0.001). Among the study cohort, the AUCs for ESM-1 were 0.813 in individuals 50 years of age or younger (n = 55) and 0.637 in individuals older than 50 years (n = 57). In RCC patients, serum ESM-1 levels were reduced 1 month (P = 0.047) and 3 months (P = 0.009) after surgery. These results suggest serum ESM-1 can serve as a serologic biomarker for diagnosing and monitoring RCC, particularly in patients younger than 50 years. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.title | Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Young Eun | - |
dc.identifier.doi | 10.18632/oncotarget.23087 | - |
dc.identifier.scopusid | 2-s2.0-85040605957 | - |
dc.identifier.wosid | 000419615500053 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.9, no.1, pp.662 - 667 | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 9 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 662 | - |
dc.citation.endPage | 667 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | MOLECULE-1 | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | MARKER | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordAuthor | carcinoma | - |
dc.subject.keywordAuthor | renal cell | - |
dc.subject.keywordAuthor | area under curve | - |
dc.subject.keywordAuthor | early diagnosis | - |
dc.identifier.url | https://www.oncotarget.com/article/23087/text/ | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.